Related references
Note: Only part of the references are listed.Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study
Samantha M. Jaglowski et al.
BLOOD (2015)
Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages
Mercedes Borge et al.
HAEMATOLOGICA (2015)
Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages
Mercedes Borge et al.
HAEMATOLOGICA (2015)
Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy
Fabio Da Roit et al.
HAEMATOLOGICA (2015)
Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL
Sarah E. M. Herman et al.
BLOOD (2014)
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity
Holbrook E. Kohrt et al.
BLOOD (2014)
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study
Jan A. Burger et al.
LANCET ONCOLOGY (2014)
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Jason A. Dubovsky et al.
BLOOD (2013)
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib
Girija Dasmahapatra et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Toll-like Receptor 2 Ligands Regulate Monocyte Fcγ Receptor Expression and Function
Prexy Shah et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond
P. Mark Hogarth et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents
Daigen Xu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
Sarah E. M. Herman et al.
BLOOD (2011)
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis
Julie A. Di Paolo et al.
NATURE CHEMICAL BIOLOGY (2011)
LyGDI, a Novel SHIP-Interacting Protein, Is a Negative Regulator of FcγR-Mediated Phagocytosis
Payal Mehta et al.
PLOS ONE (2011)
The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells
Betty Y. Chang et al.
ARTHRITIS RESEARCH & THERAPY (2011)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
B Cell Receptor and BAFF Receptor Signaling Regulation of B Cell Homeostasis
Wasif N. Khan
JOURNAL OF IMMUNOLOGY (2009)
Colocalization of the IL-12 receptor and FcγRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-γ
Sri Vidya Kondadasula et al.
BLOOD (2008)
Dual functions of Bruton's tyrosine kinase and tec kinase during Fcγ receptor-induced signaling and phagocytosis
Jenny Jongstra-Bilen et al.
JOURNAL OF IMMUNOLOGY (2008)
Signaling by Toll-like receptors 8 and 9 requires Bruton's tyrosine kinase
Sarah L. Doyle et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor-positive tumor cells is enhanced by cytokines
Julie M. Roda et al.
CLINICAL CANCER RESEARCH (2007)
Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase
Zhengying Pan et al.
CHEMMEDCHEM (2007)
FcγR-induced production of superoxide and inflammatory cytokines is differentially regulated by SHIP through its influence on PI3K and/or Ras/Erk pathways
Latha P. Ganesan et al.
BLOOD (2006)
Bruton's tyrosine kinase is not essential for LPS-induced activation of human monocytes
Rebeca Perez de Diego et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2006)
Bruton's tyrosine kinase is involved in p65-mediated transactivation and phosphorylation of p65 on serine 536 during NFκB activation by lipopolysaccharide
SL Doyle et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Bruton's tyrosine kinase:: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling
JM Lindvall et al.
IMMUNOLOGICAL REVIEWS (2005)
The inositol 3-phosphatase PTEN negatively regulates Fcγ receptor signaling, but supports Toll-Like receptor 4 signaling in murine peritoneal macrophages
XH Cao et al.
JOURNAL OF IMMUNOLOGY (2004)
Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses
A Mangla et al.
BLOOD (2004)
The serine/threonine kinase Akt promotes Fcγ receptor-mediated phagocytosis in murine macrophages through the activation of p70S6 kinase
LP Ganesan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Bruton's tyrosine kinase is required for lipopolysaccharide-induced tumor necrosis factor at production
NJ Horwood et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Src homology 2 domain-containing inositol polyphosphate phosphatase regulates NF-κB-mediated gene transcription by phagocytic FcγRs in human myeloid cells
S Tridandapani et al.
JOURNAL OF IMMUNOLOGY (2002)
Vav regulates activation of Rac but not Cdc42 during FcγR-mediated phagocytosis
JC Patel et al.
MOLECULAR BIOLOGY OF THE CELL (2002)
Macrophage effector functions controlled by Bruton's tyrosine kinase are more crucial than the cytokine balance of T cell responses for microfilarial clearance
S Mukhopadhyay et al.
JOURNAL OF IMMUNOLOGY (2002)
The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species
CIE Smith et al.
BIOESSAYS (2001)
Share Paper
